Quince Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Quince Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval for a reverse stock split to maintain Nasdaq compliance.
NASDAQ
Quince Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Quince Therapeutics is asking stockholders to approve an amendment to increase authorized shares and effect a reverse stock split at the upcoming annual meeting.
NASDAQ
Quince Therapeutics, Inc. will hold its 2024 Annual Meeting virtually on June 5, 2024, and is asking stockholders to vote on key proposals, including a reverse stock split.
NASDAQ
DEF 14A: Quince Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Proposes Reverse Stock Split
Quince Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, including proposals for director elections, a reverse stock split, auditor ratification, and executive compensation approval.